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Abstract We discuss the role of prior authorization (PA)
in supporting patient-centered care (PCC) by directing
health system resources and thus the ability to better meet
the needs of individual patients. We begin with an account
of PCC as a standard that should be aimed for in patient
care. In order to achieve widespread PCC, appropriate
resource management is essential in a healthcare system.
This brings us to PA, and we present an idealized view of
PA in order to argue how at its best, it can contribute to the
provision of PCC. PA is a means of cost saving and as such
it has mixed success. The example of the US demonstrates
how implementation of PA has increased health inequali-
ties whereas best practice has the potential to reduce them.
In contrast, systems of universal coverage, like those in
Europe, may use the cost savings of PA to better address
individuals’ care and PCC. The conclusion we offer
therefore is an optimistic one, pointing towards areas of
supportive overlap between PCC and PA where usually the
incongruities are most evident.
Key Points for Decision Makers
Prior authorization can reinforce, not detract from,
patient-centered care (PCC), depending on the
characteristics of the healthcare system.
Prior authorization tends to increase the burden on
disadvantaged patients in the US system, detracting
from PCC.
As such, prior authorization in the US system might
need to be restructured to consider PCC.
1 Introduction
Prior authorization (PA), the practice of requiring addi-
tional steps or barriers to accessing healthcare treatments,
groups patients by type, a practice that appears inimical to
the values of patient-centered care (PCC). PCC has
assumed increasing importance in medicine, placing indi-
vidual patients and their values at the center of decision
making and thus prioritizing autonomy [1, 2]. By contrast,
PA focuses on populations, contradicting doctors’ deci-
sions and restricting patient choice.
In this paper, we emphasize an element that to our
knowledge has been missing from the discussion: the role
of PA in supporting the practice of PCC by directing health
system resources to better meet the needs of individual
patients. We begin with an account of PCC as a standard in
patient care. In order to achieve widespread PCC, appro-
priate resource management is essential in a healthcare
system. This brings us to PA, and we present an idealized
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view of PA in order to argue how, at its best, it can con-
tribute to the provision of PCC. PA is a means of cost
saving and as such it has mixed success. The example of
the US demonstrates how implementation of PA has
increased health inequalities whereas best practice has the
potential to reduce them. In contrast, systems of universal
coverage, like those in Europe, may use the cost savings of
PA to better address individuals’ care and PCC. The con-
clusion we offer therefore is an optimistic one, pointing
towards areas of supportive overlap between PCC and PA
where usually the incongruities are most evident.
2 Patient-Centered Care (PCC) and Prior
Authorization (PA): Individuals and Groups
PCC insists that medicine be practiced with a focus on
individuals, their values, and their involvement in decision
making. PCC places distinct emphasis on medical decision
making guided by patients’ objectives and values. This
requires patients to participate in their treatment, and PCC
offers an account characterizing good health outcomes as
those that are meaningful to the patient [3]. This means that
when approaching treatment decisions, physicians should
set aside their own concerns and instead focus on those of
the patient [1, 4]. PCC is an approach to the values that
guide decision making, distinct from personalized medi-
cine and from the view of patients as customers, which
entails a shift to performance measures like customer sat-
isfaction. PCC relates to shared decision-making and the
bearing that patients’ values have; it is not the same as
patient satisfaction [5]. The contributions of PCC stem
from a normative view of what matters in healthcare
decision making and the doctor–patient relationship.
Our discussion of PCC rests on two essential features: it is
an expression of autonomy on the part of patients regarding
their objectives with their healthcare and their values, and it
is a particular nuance to the doctor–patient relationship since
it requires doctors to set aside their own objectives, placing
the patient at the center of the care team. Trust in this rela-
tionship is essential in order for patients to believe their
values are appropriately considered, and PCC strengthens
the doctor–patient relationship [3]. As a concept and
movement in healthcare, PCC seems to name what we each
hope to experience as patients: individual attention to and
involvement of our concerns and values.
Although accomplishing PCC does not rely on techno-
logical innovations or expensive treatments, it does require
investment in the health system. In order to successfully
implement PCC, physicians must have enough time with
patients to discuss their values, incorporate them into a
treatment plan, and manage transitions between providers
so that the patients’ values stay at the forefront of the
clinical journey. In primary care, for example, this would
necessitate longer patient visits, decreasing the number of
patients seen in a day, and thereby increasing the number
of primary care physicians needed in order to cover longer
consultations. This has obvious cost implications and also
presents a challenge since there is a consistently predicted
shortfall in future physician numbers and increasing strain
on their time [6, 7]. In order to widely implement PCC, it
seems likely that resources will have to be reshuffled or
added to existing healthcare systems.
Because of the demands PCC places on systems, PA
may play a role in resource management. PA is one of
many tools for cost effectiveness that is meant to introduce
savings and efficiencies into a health system. We use a
fairly broad definition of PA that includes insurer or payer
requirements for additional approvals for treatment or step
therapy—the requirement to try a less expensive alternative
first [8]. PA is a form of cost management in a health
system that reduces costs by grouping patients into diag-
nostic or treatment categories and restricting their choice of
treatments. For example, PA is commonly used as an
additional safety check to enforce a consideration of the
risk–benefits (and costs) of a particular procedure, like CT
scans or imaging for low back pain [9]. PA may also cover
tiered systems in which payers require that a lower-cost
intervention be used before trying a more expensive one,
even if the first may be somewhat less effective or have a
larger side effect profile (though still clinically appropriate)
[10]. There are two main reasons why PA is implemented:
it can act as a safety measure and to reduce costs. In this
paper, we assume physicians are prescribing and ordering
in a safe manner and focus on the latter reason: PA is a tool
for resource management and cost control.
PA is one method for healthcare savings and cost-ef-
fectiveness implementation, and it has been implemented
in a number of systems. In the UK, PA is a common feature
of the NHS: some procedures are considered ‘low priority’
and an Individual Funding Request application must be
made to access them [11, 12]. At a national level, the
National Institute for Health and Care Excellence (NICE)
makes cost-effectiveness determinations for the NHS. In an
example of step therapy, the guidance on Alzheimer’s and
dementia requires that memantine, the more expensive
treatment, only be used in more severe cases or if alter-
native treatments are not tolerated [13]. The Dutch
healthcare system, which has adopted patient participation
in decision making as an important part of patients’ rights,
relies on primary care providers to act as gatekeepers since
their referral is necessary to see a specialist. It also groups
pharmaceuticals into ‘therapeutic equivalents’, limiting
reimbursements to the lower-cost options—if patients
choose more expensive options then they pay the differ-
ence unless a physician certifies its clinical necessity [14].
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These are examples of systems that promote PCC while
simultaneously implementing the cost and efficiency
measures of PA.
Because PCC is focused on the individual and PA
necessarily lumps patients into groups (low back pain,
Alzheimer’s, etc.), the concepts are essentially at odds. The
one seeks out individuality while the other looks for
homogeneity. PA and PCC are fundamentally different
because of the way they view people either as homogenous
groups or as heterogeneous individuals. Despite this dif-
ference, if our aim is to increase the use of PCC, then PA is
a tool that can contribute to achieving that aim. In the
following, we present an ideal version of PA that would
better the healthcare system via resource stewardship,
allowing for improvements like PCC.
3 An Account of PA as Stewardship
PA directs resources within a healthcare system. An ideal
account of PA is that it is a tool of distributive justice and
stewardship, and as such it is intended to promote better
care for a whole class of patients rather than individuals.
This means that though an individual takes on a burden, the
end aim is to promote better health across the whole group
of patients, including that individual. For example,
requiring patients to try less expensive treatments first
means cost savings if they prove effective. Extra hurdles
for procedures that may not be necessary reduces use and
cost rather than promoting a culture of overtesting. These
savings of resources—financial, facility availability, or
otherwise—ought to feed back into the healthcare system
in order to provide more care for its population. Guiding
physicians to more cost-effective treatments is not an end
in itself, but a way to strengthen a health system so that the
economic choices result in increased access [4].
Canadian health systems have been addressing this very
issue, as they have struggled to meet the demands of PCC,
including increased access to primary care and easing
transitions between parts of the healthcare system. Inno-
vations have included triage tools and prioritizations for
specialist referrals. These new tools are a form of cost
saving and efficiency that are meant to provide the kind of
PCC desired in the system [7]. Good resource stewardship
strengthens the health system and increases the resources
available to meet needs, and it is in this role that PA has its
part to play in promoting the PCC approach.
A useful analogy for PA is to look at the role of
antimicrobial stewardship programs; through guarding
resources they address individual needs as well as those of
the larger population. Antimicrobial stewardship programs
are increasingly common in hospitals and include expert
insight and guidelines both for determining the best
antibiotic for a particular patient as well as protecting the
common good by decreasing resistance, overuse, and cost
[15]. The proper management of antibiotics is important for
the individual patient’s outcome, and it is also critical for
the health of the population and future patients.
One objection to PA is that it removes from physicians
and patients the ability to make autonomous decisions due
to constraints by an external party. Regarding physicians,
PA intrudes into the doctor–patient relationship and con-
travenes their clinical judgement. While this is true, PA
does not rely on bedside rationing. Therefore, the profes-
sional duties of doctors are still to consider what is best for
the patients in front of them without having to calculate the
needs of others. PA makes these decisions, allowing
physicians to cultivate their relationships with patients
without simultaneously raising questions about whose
interests take priority. With PA, physicians remain patient
focused though the external requirements limit the deci-
sions patients and providers may make.
However, where PCC places the patient at the center of
decision making, PA limits the options for patients. PA is
designed for populations and efficiently addressing their
needs, so it does not address the nuances of individuals’
decision making or the values that inform a person’s choices,
which is what PCC prioritizes. It is in this respect that PA and
PCC are most fundamentally at odds. The Canadian example
illustrates practical efforts to reconcile the decrease in patient
choice with PCC: in order to increase access to primary care
providers and increase patient involvement, efficiencies have
been made elsewhere in the system [7]. Similarly, Sweden’s
healthcare system has brought PCC and patient rights to the
forefront, but it still uses a national system of pharmaceutical
benefits that includes step therapy [16, 17]. In these instances,
there is a trade-off between limiting patient choice and pro-
moting wider access to healthcare, patient education, and
involvement in decision making. In systems of universal
coverage, there is a justified integration between PA and
PCC, since patients are treated equally in taking on burdens
and benefits.
In sum then, we have argued that the ideal account of PA
can be a tool to enhance the possibilities of PCC because the
stewardship of resources will provide greater opportunity to
engage and provide for patients. PA also removes certain
decisions from physicians and patients so that resource
stewardship can occur but does so outside of the context of
the doctor–patient relationship and individuals’ values.
4 Pragmatic Problems—the Example of the US
So far, the argument we have given has rested on
assumptions about universal health systems and an ideal-
ized motivation for PA. We assumed that the health system
Prior Authorization as a Potential Support of Patient-Centered Care 373
aims to reinvest its savings into improving care and that
those burdened by PA also stand to benefit from the rein-
vestment of additional resources. This excludes the (very
real) possibility that PA is used to increase profit and that
the patients affected are not those who gain from invest-
ment into PCC. In the US, omnipresent disparities and
inequities of the health system mean that the ideal version
we presented above is not practiced, and PA results in
further inequities affecting the worst off.
In the US, PA gained traction in Medicaid, the Federal-
and state-funded insurance program for the poor, during the
1990s as programs began to adopt PA as a way to control
costs. Medicaid now widely uses PA to control pharma-
ceutical and service costs, as do a number of private
insurers [8, 18, 19]. Medicaid patients tend to be poorer,
younger, more likely to belong to a racial/ethnic minority,
and more likely to have a chronic condition than patients of
other insurers [18]. Patients on Medicaid are unlikely to
have the resources to circumvent PA or access treatments
using their own finances.
PA compounds the health disparities present in the US
since its practice restricts patient choice to a question of
willingness to pay. This burden differentially affects
patients based on their personal means to circumvent PA
requirements. The introduction of PA into Medicaid led to
decreased access to prescription pharmaceuticals for its
enrollees, even when cost sharing was consistent with
private insurer rates [18]. Reduced access to mental health
treatment has received much focus; mental health patients
were less likely to start new treatments and, because of PA
rules for atypical antipsychotics, overall antipsychotic
prescribing decreased [10, 20–22]. The changes in phar-
maceutical use that follow the introduction of PA are also
likely to be amplified amongst Medicaid users and those
with reduced financial means who cannot seek out alter-
natives [20]. Step therapy PA limits patient choice to the
cheapest option or a decision about willingness to pay. For
some patients, this will be a possible trade-off, but for the
worst off, there will be no choice at all.
The effect of PA on poorer patients may also be seen
in systems with universal health coverage. The Dutch,
for example, set reimbursement rates by the lowest cost
treatment in a group of comparable effectiveness, and
insurers identify preferred pharmaceuticals and only
reimburse for the lowest cost option [14]. In systems that
mix PA with the option to purchase higher-cost treat-
ments, patients with limited financial means will bear the
greatest burden. In the US, this is all the more stark since
those patients do not benefit from increased spending on
their interests, such as investment in PCC. The imple-
mentation of PA raises justice concerns for the health
system and its effects on disadvantaged patient
populations.
A final concern is that PA, as insurers practice it in the
US, simply shifts costs from insurers and payers to
physician practice and patients who must invest time into
navigating the rules and responding to requests for autho-
rization. PA shifts costs from the payer (the insurer) to the
physician and medical staff when they are required to
spend time approving treatments and arguing on behalf of
their patients [23]. Insofar as PA simply shuffles about
costs and moves them from insurer to physician, it fails as a
cost-saving measure across the system and off-loads costs
to already over-worked physicians and practices. When this
is the case, then PA is used merely as a cost-reducing
measure for insurers rather than as one that will better the
system overall.
The reality of PA means that we cannot endorse its
current practice in the US. As PA is used, it reflects some
of the goals we outlined above regarding resource man-
agement, but it has been implemented in such a way as to
reduce patient confidence and introduce new equity and
access concerns. At its best, PA could play an important
role in resource stewardship, which would provide the
opportunity to spread practices like PCC. In systems of
universal coverage, like the UK’s NHS, PA can be applied
uniformly without creating further disparities to access and
coverage. Clear communication about reasons and proce-
dures may address concerns and result in agreement on
measures like PA and what constitutes reasonable excep-
tions [24]. Moving forward with PA, health systems should
be aiming to promote the health of the patient populations
they serve while minimizing detrimental effects and
potential inequities.
5 Pulling Together PCC and PA
But what of PCC? PCC is itself an ideal that expresses a
way of practicing medicine and relating to patients that
seems threatened by billing codes, rushed visits, and
competing incentives. It is an ideal about regard for the
patient and prioritizing individuals, their values, and their
central role in a complex web of care. This is a standard of
doctor–patient relationship, integrated care, and clinical
encounter that is intrinsically valuable. It requires time,
physician skill, doctor–patient trust, and systemic support.
Across the globe, healthcare systems increasingly seek
to involve patients, heighten their autonomy, and centralize
them and their values during their medical care. Doing so
requires investment in integrated, holistic healthcare sys-
tems. This is where the ideal account of PA and PCC can
merge: supporting a health system with reasonable cost-
control measures contributes to the aim of ultimately pro-
viding better, considered care to a growing patient
population.
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We conclude, then, with an optimistic prescription for
the use of PA in order to enhance PCC. A well managed
and determined system of PA, with physician buy-in, rea-
sonable requirements, and review for exceptions, may be
implemented as a cost-saving measure that will shepherd
resources in a health system. Resource stewardship is
essential for a robust health system, providing the time and
ability for physicians to practice PCC. If our aim is
healthcare focused on the individual and a high standard of
care and involvement, we must also turn attention to the
complementary concept of how resource decisions can help
achieve that aim.
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